No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
No Data
Press Release: Ocular Therapeutix(TM) Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Ocular Therapeutix (OCUL) Gets a Buy From Piper Sandler
Investors Await Earnings Reports, Tech Stocks Take Hit as US Futures Fall Sharply Pre-Bell
Institutional Investors Have a Lot Riding on Ocular Therapeutix, Inc. (NASDAQ:OCUL) With 64% Ownership
The One-year Returns Have Been Notable for Ocular Therapeutix (NASDAQ:OCUL) Shareholders Despite Underlying Losses Increasing
Piper Sandler Sticks to Their Buy Rating for Ocular Therapeutix (OCUL)